Autopsy report · NCT03379493

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

“Sponsor's Decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 10 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Eureka Therapeutics Inc.

Sponsor type

Industry

Conditions

Lymphomas Non-Hodgkin's B-Cell

Interventions

ET190L1 ARTEMIS™ T cells

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Everolimus With and Without Temozolomide in Adult Low Grade Glioma
  “Sponsor decision” (98% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.